Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634348 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
A Phase 4 study of Schizophrenia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 256
- Enrollment target
- 20
- Study locations
NCT00634348: Completed Phase 4 study of Schizophrenia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00634348 is a Phase 4 study of Schizophrenia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 256 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634348, a Phase 4 study of Schizophrenia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 256 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
Conditions Studied
Interventions
- DRUG Ziprasidone
- DRUG Aripiprazole
Study Locations (20)
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Cerritos
- Pfizer Investigational Site - Culver City
- Pfizer Investigational Site - Garden Grove
- Pfizer Investigational Site - Glendale
- Pfizer Investigational Site - La Mesa
- Pfizer Investigational Site - Newport Beach
- Pfizer Investigational Site - Paramount
- Pfizer Investigational Site - Riverside
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - Torrance
- Pfizer Investigational Site - Upland
Maryland
- Pfizer Investigational Site - Baltimore
- Pfizer Investigational Site - Rockville
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Florida
- Pfizer Investigational Site - Hialeah
Louisiana
- Pfizer Investigational Site - Shreveport
Missouri
- Pfizer Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-03 |
| Phase | Phase 4 |
What the finished NCT00634348 record still lists
NCT00634348 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Ziprasidone is the first listed.
NCT00634348 names 20 study sites across 6 states, led by California, Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00634348 about?
NCT00634348 is a clinical study titled "A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients". The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
What is the current status of trial NCT00634348?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 256 participants. The study started on 2004-04. Estimated completion is 2005-03.
What conditions does trial NCT00634348 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00634348?
The interventions under investigation include: Ziprasidone (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00634348?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00634348 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00634348's enrollment target sits among peer trials
256 76th of 315 higher than 240 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia